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Objectives: The trematocidal properties of a synthetic peroxide, 1,2,4-trioxolane (OZ78) were determined
both in vivo and in vitro.
Methods: Two weeks post-infection Echinostoma caproni-infected mice were administered single oral
doses of 400–1000 mg/kg OZ78. Fasciola hepatica-infected rats were treated orally with 50–400 mg/kg
OZ78 3 and 8–9 weeks post-infection. Worm burden reductions were assessed against untreated control
animals. Adult F. hepatica were observed by scanning electron microscopy (SEM) after recovery from
the bile duct of a rat 3 days after administration of a single oral dose of 100 mg/kg OZ78 and after in vitro
exposure to concentrations of 1, 10 and 100 mg/mL OZ78.
Results: In the E. caproni–mouse model 100% worm burden reductions were achieved with a single oral
dose of 1000 mg/kg OZ78. A single dose of 100 mg/kg OZ78 resulted in worm burden reductions of 100%
against juvenile and adult F. hepatica. F. hepatica recovered from rats 3 days post-treatment displayed
feeble activity and some flukes had died. Typical features revealed by SEM included extensive blebbing
and sloughing. Exposure of F. hepatica to 10–100 mg/mL OZ78 in vitro resulted in the death of all
trematodes. F. hepatica showed focal blebbing and sloughing of the tegument at all concentrations
investigated.
Conclusions: Our data indicate that OZ78 is highly efficacious against F. hepatica and E. caproni and
provide a sound platform for identification of a synthetic peroxide drug development candidate against
major trematode infections.
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Introduction
Fascioliasis is a zoonotic disease of considerable public health and
great veterinary significance. The causative agents of fascioliasis
are liver flukes, i.e. Fasciola hepatica and Fasciola gigantica.
Human fascioliasis occurs worldwide, with the highest number
of infected people reported in South America, Cuba, Western
Europe, Egypt and the Islamic Republic of Iran.1 An estimated
91 million people are at risk and as many as 17 million people
might be infected with either F. hepatica or F. gigantica.2,3
Typical symptoms of the disease include fever, urticaria, pain in
the right hypochondrium, hepatomegaly, hypergammaglobulinae-
mia and marked eosinophilia, cholangitis and cholestasis.4 Today,
treatment of human fascioliasis relies on a single drug, i.e.
triclabendazole. However, since this drug is currently registered in
only four countries,5 novel treatment options are of high priority.
There is considerable concern about the development of resistance
to triclabendazole, which already hampers use of this drug in
veterinary medicine.6
We have recently reported fasciocidal properties of the
artemisinins, which are best known for their antimalarial7
and to a lesser extent their antischistosomal properties.8 In the
F. hepatica-rat model we found that single oral doses of
200 mg/kg artemether and 400 mg/kg artesunate resulted in
worm burden reductions of 100%.9 However, the artemisinins
have chemical, economic and biopharmaceutical liabilities.10
Hence, we were motivated to evaluate the fasciocidal properties
of other peroxides, particularly the antimalarial synthetic 1,2,4-
trioxolanes (secondary ozonides, OZs). The OZs exhibit structural
simplicity, ease of synthesis and improved pharmacokinetic
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parameters when compared with the artemisinins.10 The anti-
malarial OZ277 has recently entered Phase II clinical trials. For
the present study we selected OZ78, which has weak antimalarial
but promising antischistosomal properties (S. H. Xiao,
J. Keiser, J. Chollet, Y. Dong, J. Utzinger, M. Tanner and
J. L. Vennerstrom, unpublished data). Previous research revealed
that OZ78 is not mutagenic and has a toxicological profile similar
to artesunate in a multiple dose 5 day exploratory toxicity
experiment in male Wistar rats.10
We firstly present our approach to screen for trematocidal
activity employing an Echinostoma caproni–mouse model.
Emphasis is then placed on the evaluation of the fasciocidal
properties of OZ78 after single oral doses at various concentra-
tions administered to rats infected with either juvenile or adult
F. hepatica. Finally, we document drug-induced alterations on
F. hepatica following exposure to OZ78 in vitro and after
administration of OZ78 in vivo by means of scanning electron
microscopy (SEM).
Materials and methods
Ethical clearance, drug, parasites and host–parasite
models
All animal studies presented here were approved by regulatory
authorities following Swiss national regulations (permission
no. 2070) and carried out at the Swiss Tropical Institute (Basel,
Switzerland).
The chemical structure of OZ78 is depicted in Figure 1. OZ78 was
synthesized at the College of Pharmacy, University of Nebraska
Medical Center (Nebraska, USA). OZ78 was prepared in suspen-
sions in 7% (v/v) Tween 80 and 3% (v/v) ethanol before oral
administration.
Metacercarial cysts of E. caproni were removed from the kidney-
pericardial region of infected snails of the species Biomphalaria
glabrata at our laboratories as described previously.11 Metacercariae
(Cullompton isolate) of F. hepatica were purchased from
Mr G. Graham (Addlestone, UK).
Female NMRI mice (n = 18, age: 5 weeks, weight: 25 g) and
female Wistar rats (n = 48, age: 5 weeks, weight: 100 g) were
purchased from RCC (Itingen, Switzerland). Animals were kept in
groups of 5 inmacrolon cages in environmentally controlled conditions
(temperature: 25C; humidity: 70%; 12 h light/dark cycle) and
acclimatized for 1 week. They had free access to water and rodent diet.
In vivo studies E. caproni
Eighteen mice were infected intragastrically with 35 metacercarial
cysts of E. caproni each. Two weeks post-infection, 3 groups of
4 mice were treated intragastrically with OZ78 at single doses of 400,
800 and 1000 mg/kg. The remaining 6 mice were left untreated, and
hence they served as control. Three days post-treatment, mice were
euthanized by CO2. At necropsy, the intestines were removed from
the pylorus to the ileocaecal valve, placed in a Petri dish and opened
longitudinally. All E. caproni worms were removed and counted.
In vivo studies F. hepatica
Adult infection. Thirty-two rats were infected intragastrically with
25 metacercarial cysts of F. hepatica each. Eight to nine weeks post-
infection, 4 groups of 5 rats were treated orally with OZ78 at single
doses of 50, 100, 200 and 400 mg/kg. Twelve untreated rats served as
a control group. Ten days post-treatment, rats were euthanized by
CO2. At necropsy F. hepatica were harvested from the excised bile
ducts and counted.
Juvenile infection. Fifteen rats were infected intragastrically with
25 metacercarial cysts of F. hepatica each. Three weeks post-
infection, 2 groups of 5 rats were treated orally with OZ78 at a single
oral dose of either 50 or 100 mg/kg. Five untreated rats served as
controls. Eight weeks post-infection rats were killed with the CO2
method and all F. hepatica were recovered from the bile ducts.
In vivo SEM observations on F. hepatica
One rat, infected intragastrically with 25 metacercarial cysts of
F. hepatica, was administered a single oral dose of 100 mg/kg OZ78
at week 12 post-infection. The rat was killed by CO2 at 3 days post-
treatment. At necropsy F. hepatica were recovered from the excised
bile ducts and processed for SEM studies as described below. Four
flukes were examined.
In vitro studies
F. hepatica recovered from the rats of the control group were quickly
washed with 0.9% (w/v) NaCl and incubated in 6-well plates
(Costar), placing two F. hepatica per well. Culture medium in each
well contained 5 mL of NCTC 135 (Gibco), which was supplemented
with antibiotics (50 mg/mL streptomycin and 50 U/mL penicillin;
Gibco). For one series of experiments 10% (v/v) fetal calf serum was
added to the medium. Four trematodes were used for each control and
experimental group.
Stock solutions of OZ78 were prepared in 60% (v/v) DMSO.
The flukes were incubated with three serial drug dilutions of 1, 10 and
100 mg/mL for up to 72 h. The control well contained the highest
concentration of solvent—0.06% DMSO. Cultures were kept at 37C
in an atmosphere of 5% CO2 and observed after exposure for 24, 48
and 72 h under a dissecting microscope. F. hepatica were considered
dead if no movement was observed for 2 min. Flukes incubated in the
medium further supplemented with calf serum were collected at 24,
48 and 72 h and prepared for SEM observations as described below.
SEM observations
F. hepatica were rinsed with 0.9% (w/v) NaCl and fixed with 2.5%
(v/v) glutaraldehyde in a PBS buffer for 24 h at room temperature.
After rinsing with PBS buffer, the specimens were washed with dis-
tilled water, dehydrated and critically point dried (Bomar SPC-900;
Tacoma, USA). After sputter-coating with gold of 20 nm (Baltec Med
020, Tucson, USA) F. hepatica were mounted on aluminium stubs
and observed in a high-resolution SEM (Philips XL30 ESEM;
Eindhofen, The Netherlands) at an accelerating voltage of 5 kV.
Statistical analysis
Average worm burdens were expressed as arithmetic means,
including values of zero for animals with no worms. The Kruskal–
Wallis (KW) test was used to compare the medians of the responses
between the treatment and control groups. A difference in median
was considered to be significant at a level of 5%. Statistical analyses
were done with version 2.4.5 of Statsdirect statistical software








Effect of OZ78 on adult E. caproni harboured in mice
The effects of OZ78 on adult E. caproni harboured in mice
were assessed by worm burden reductions and the results are
summarized in Table 1. OZ78 given at a dose of 1000 mg/kg
killed all the worms (KW = 7.01; P = 0.008). At doses of 800 and
400 mg/kg, OZ78 reduced worm burdens insignificantly by
65.4% (KW = 2.2; P = 0.129) and 10.1% (KW = 0.75; P = 0.386).
Effect of OZ78 on adult F. hepatica harboured in rats
The results of the effects of OZ78 on adult F. hepatica harboured
in rats are summarized in Table 2. Administration of single oral
doses of 100 mg/kg and above resulted in worm burden reductions
of 100% (KW = 10.32; P = 0.001). Even at 50 mg/kg, the lowest
dose investigated, a statistically significant worm burden
reduction of 52.7% was obtained (KW = 4.53; P = 0.033).
Effect of OZ78 on juvenile F. hepatica harboured in rats
In Table 3 we present the results of the effects of 50 and
100 mg/kg single oral doses of OZ78 on juvenile F. hepatica
harboured in rats. A 100% worm burden reduction was observed
with 100 mg/kg OZ78 (KW = 7.81; P = 0.005). Administration of
OZ78 at a dose of 50 mg/kg achieved a 66.7% worm burden
reduction (KW = 5.47; P = 0.019).
In vitro studies
Serum-free medium. Exposure of F. hepatica in a serum-free
medium containing OZ78 at 100 mg/mL for 24 h resulted in
the death of all trematodes. They showed extensive blebbing.
F. hepatica exposed for 24 h to 10 mg/mL OZ78 showed normal
movements. After exposure for 48 h, the flukes showed reduced
activity. Another 24 h later, all trematodes had died and
numerous blebs could be observed on their surface.
Finally, F. hepatica exposed to 1 mg/mL OZ78 for 72 h showed
slightly reduced movement, but there were no signs of surface
changes.
Medium supplemented with 10% (v/v) fetal calf serum. F. hepatica
exposed to 100 mg/mL OZ78 in a medium supplemented
with 10% (v/v) fetal calf serum were still alive after 24 h, but
they showed reduced movements and occurrence of blebs on
the tegument. The flukes died 48–72 h after incubation at this
concentration: they showed extensive blebbing and a coiled
appearance. SEM pictures taken from flukes 24 h after treatment
with 100 mg/mL revealed sloughing and blebbing at the ventral
and dorsal surfaces (Figure 2a). F. hepatica exposed to 10 mg/mL











Control – 6 – 21.7 (6.0) –
OZ78 400 4 0 19.5 (6.1) 10.1
800 4 3 7.5 (15.0) 65.4
1000 4 4 0 100







cured Mean worm burden (SD)
Total flukes recovered Total worm
burden
reduction (%)live dead
Control – 12 – 5.5 (2.6) 66 0 –
OZ78 50 5 0 2.6 (2.0) 13 0 52.7
100 5 5 0 0 2 100
200 5 5 0 0 6 100
400 5 5 0 0 3 100







Total flukes recovered Total worm
burden
reduction (%)Treatment Dose (mg/kg) live dead
Control – 5 – 4.8 (2.2) 24 0 –
OZ78 50 5 0 1.6 (0.8) 8 0 66.7
100 5 5 0 0 0 100
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OZ78 for 48 h showed a slightly reduced movement and also
blebbing and sloughing on the dorsal tegument (Figure 2b), but
the trematodes were still alive after 72 h. Flukes incubated
for 72 h with 1 mg/mL OZ78 were still moving normally, but
showed tegumental alterations including sloughing (image not
shown).
In vivo SEM observations
F. hepatica recovered from the central bile duct of rats 3 days
after oral administration of a single dose of 100 mg/kg OZ78 were
either dead (n = 2) or showed only feeble activity (n = 4). Blebs
were visible on the ventral and dorsal tegument of both dead and
alive specimens (Figure 3a). Many flukes showed sloughing of the
tegumental surfaces (Figure 3b).
Discussion
We recently reported that the artemisinins exhibit activity against
E. caproni in the mouse model;11 subsequently these findings
were confirmed against one of the major liver flukes, i.e.
F. hepatica, in the rat model.9 In view of these results, we were
motivated to investigate further whether other peroxide com-
pounds possess fasciocidal properties. We selected the anti-
malarial 1,2,4-trioxolanes (OZs) because these compounds are
characterized by improved chemical and biopharmaceutical
parameters compared with the artemisinins.10
It is widely acknowledged that E. caproni is a suitable
laboratory model to study intestinal trematodiasis.12 We have
demonstrated the utility of the E. caproni–mouse model to screen
compounds for their trematocidal activity.11 In view of the ease of
maintenance and relatively short life cycle, this host–parasite
model has become our primary screen. Similar to the artemisi-
nins11 high doses of OZ78 were required to show an effect against
E. caproni. Since OZ78 achieved a 100% worm burden reduction
in E. caproni-infected mice, this compound progressed to the
F. hepatica–rat model.
We found that OZ78 was highly efficacious against adult
F. hepatica; complete worm burden reductions were obtained at a
single oral dose of 100 mg/kg. At half this dose we still found
a statistically significant worm burden reduction exceeding 50%.
For comparison, a slightly lower dose (40 mg/kg) of triclabenda-
zole, the drug of choice for fascioliasis, reduced adult worm
burdens by 99% in F. hepatica-infected rats.13 Similar to
Figure 3. SEM observation of adult F. hepatica recovered from rat bile ducts 3 days after the administration of OZ78 at a dose of 100 mg/kg. (a) Blebbing
(indicated by ‘b’) visible on the dorsal tegument. (b) Extensive sloughing (indicated by ‘s’) of the ventral tegument.
Figure 2. SEM of adult F. hepatica after incubation with 10 and 100 mg/mL OZ78 in NTCT-135 medium supplemented with 10% (v/v) fetal calf serum. (a)
Blebbing (indicated by ‘b’) and sloughing (indicated by ‘s’) on the dorsal tegument 24 h after incubation with 100 mg/mL OZ78. (b) Severe swelling and
sloughing (indicated by ‘s’) visible on the dorsal tegument 48 h after incubation with 10 mg/mL OZ78.
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triclabendazole, but in contrast to several existing fasciolicides
such as closantel or closurlon14 OZ78 showed excellent activity
against juvenile F. hepatica; a single oral dose of 100 mg/kg
cured juvenile F. hepatica infections harboured in rats.
The improved pharmacokinetic properties of OZ78 might
explain why much lower doses of OZ78 cured F. hepatica-
infected rats when compared with the artemisinins. For example,
a 4-fold higher dose of artesunate (400 mg/kg) was necessary to
achieve complete worm burden reductions in rats infected with
adult F. hepatica.9 OZ78 in rats has an oral bioavailability of
74.1%, which is several-fold higher than the oral bioavailabilities
of either artemether (1.4%) or artesunate (23.3–32.3%). The half-
life of OZ78 in rats is 2 h, which is more than double that of
artesunate (0.47 h).10 Importantly, OZ78 was better tolerated by
the F. hepatica-infected rats than artesunate; at an artesunate dose
of 400 mg/kg, 3 of 5 rats died within 24–96 h while no fatalities
occurred following OZ78 administration at the same dose.9
Our temporal SEM investigations have shown that, very
similar to artesunate and artemether, OZ78 acts very slowly on
F. hepatica. Seventy-two hours post-treatment some flukes
recovered from the bile duct still showed feeble activity.
Compared with the artemisinins, tegumental damage was more
pronounced, as an extensive swelling and sloughing was detected
on F. hepatica 3 days following the administration of OZ78.
Damage and loss of the spines of F. hepatica has been observed
frequently following treatment with several fasciolicides.15 The
tegument of Fasciola spp. is the interfacing layer that helps the
parasite to maintain its homeostasis, and to escape the host’s
immune attacks.16 Hence, once the tegument or the spines
of F. hepatica are damaged, drugs can easily penetrate to the deep
tissues causing substantial and widespread damage.15 We
observed an increased susceptibility to OZ78 in vitro in a non-
serum supplemented medium. A similar observation was made
in a previous study, which evaluated the fasciocidal properties of
phenolic, halogenated diphenyl, salicylanilide, benzimidazole
and diaminophenoxyalkane anthelmintics in serum-free and
serum-supplemented media.17 The increased potency of the
fasciolicides in the absence of serum has been explained by
drug serum protein binding, which renders the drugs less
accessible to the flukes.17
In conclusion, we have presented the first evidence of the
potent fasciocidal properties of a 1,2,4-trioxolane and this is
supported by in vivo and in vitro studies and underscored by SEM
observations. Our results call for additional studies in larger
mammals, e.g. sheep infected with F. hepatica or F. gigantica.
These investigations could go hand-in-hand with a vigorous
multidimensional screening and lead optimization process with
the aim to gain a better insight into the structural characteristics
necessary for optimal trematocidal activity of the synthetic 1,2,4-
trioxolanes.
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